Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5898930 | Diabetes Research and Clinical Practice | 2016 | 8 Pages |
â¢Concomitant thiazolidinedione + fibrate use was associated with a â¼1.5- to 2.5-fold increased risk of severe hypoglycemia.â¢This increased risk generally manifested after the first month of concomitant use.â¢Severe hypoglycemia occurs in some patients receiving a thiazolidinedione, even without concomitant exposure to insulin or a sulfonylurea.â¢The apparent drug interaction between thiazolidinediones and fibrates is an underappreciated cause of severe hypoglycemia.â¢Clinicians should be attuned to both immediate- and delayed-onset hypoglycemia in their patients treated concomitantly with thiazolidinediones and fibrates.
We conducted high-dimensional propensity score-adjusted cohort studies to examine whether thiazolidinedione use with a statin or fibrate was associated with an increased risk of severe hypoglycemia. We found that concomitant therapy with a thiazolidinedione + fibrate was associated with a generally delayed increased risk of severe hypoglycemia.